NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA), today announced that data from a study of the Fc gamma 3A receptor (FCGR3A) in patients with follicular non-Hodgkin’s lymphoma (NHL) validates the use of genotyping for genetic variants in the Fc gamma receptors for predicting response to rituximab. These findings, to be presented by Clinical Data’s PGxHealth division at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, June 4-8, 2010, build upon previous data which demonstrated that the FCGR3A genotype is associated with response to induction and maintenance therapy with rituximab in certain NHL patients.
